Given the importance of PI3K signalling in breast cancer and the overwhelming degree of validation for PI3K as a therapeutic target, it is not surprising that the pharmacological inhibition of PI3Ks are considered to be among the most promising strategies in drug development for cancer therapy [11]. This evidence concerns the gene PIK3CA and breast cancer.